U.S. Generic Drug Probe Seen Expanding After Guilty Pleas
- Ex-Heritage executives said to cooperate with prosecutors
- Charges are first in U.S. probe said to involve a dozen firms
This article is for subscribers only.
Two executives of a small generic-drug maker are preparing to plead guilty to price-fixing charges and will cooperate with U.S. prosecutors examining allegations of widespread collusion among drug manufacturers, according to people with knowledge of the matter.
, a former chief executive officer of Heritage Pharmaceuticals Inc., and , an ex-president, were charged in Philadelphia, according to court filings unsealed on Wednesday. Each was charged in a criminal information with two counts of conspiring with other drugmakers, which weren’t identified, to fix the prices of an antibiotic and a drug used to treat diabetes.